{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:09:53Z","timestamp":1790359793411,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s11523-015-0416-3","type":"journal-article","created":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T23:33:26Z","timestamp":1455233606000},"page":"115-122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Lenvatinib: A Review in Refractory Thyroid Cancer"],"prefix":"10.1007","volume":"11","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,12]]},"reference":[{"key":"416_CR1","unstructured":"Cancer ResearchUK. Thyroid cancer incidence in Europe and worldwide. http:\/\/www.cancerresearchuk.org . Accessed 4 Sep 2015."},{"key":"416_CR2","unstructured":"EUCAN cancer factsheet: thyroid cancer. http:\/\/eco.iarc.fr . Accessed 4 Sep 2015."},{"key":"416_CR3","unstructured":"SEER stat fact sheets: thyroid cancer http:\/\/seer.cancer.gov . Accessed 4 Sep 2015."},{"key":"416_CR4","first-page":"281","volume":"8","author":"S Jasim","year":"2014","unstructured":"Jasim S, Ozsari L, Habra MA. Multikinase inhibitors use in differentiated thyroid carcinoma. Biol Tar Ther. 2014;8:281\u201391.","journal-title":"Biol Tar Ther"},{"issue":"6","key":"416_CR5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1758834014548188","volume":"6","author":"F Worden","year":"2014","unstructured":"Worden F. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol. 2014;6(6):267\u201379.","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"416_CR6","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1210\/jc.2011-1109","volume":"96","author":"JD Brierley","year":"2011","unstructured":"Brierley JD. Update on external beam radiation therapy in thyroid cancer. J Clin Endocrinol Metab. 2011;96(8):2289\u201395.","journal-title":"J Clin Endocrinol Metab"},{"key":"416_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/618985","author":"NL Busaidy","year":"2012","unstructured":"Busaidy NL, Cabanillas ME. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res. 2012. doi: 10.1155\/2012\/618985 .","journal-title":"J Thyroid Res"},{"issue":"8","key":"416_CR8","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"416_CR9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1210\/jc.2005-1534","volume":"91","author":"RJ Robbins","year":"2006","unstructured":"Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498\u2013505.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"416_CR10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1758834014551936","volume":"7","author":"T Alonso-Gordoa","year":"2015","unstructured":"Alonso-Gordoa T, Diez JJ, Duran M, et al. Advances in thyroid cancer treatment: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(1):22\u201338.","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"416_CR11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CAD.0000000000000247","volume":"26","author":"E Wang","year":"2015","unstructured":"Wang E, Karedan T, Perez CA. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond. Anti-Cancer Drugs. 2015;26(7):689\u201397.","journal-title":"Anti-Cancer Drugs"},{"issue":"3","key":"416_CR12","first-page":"483","volume":"13","author":"J-M G\u00f3mez-S\u00e1ez","year":"2013","unstructured":"G\u00f3mez-S\u00e1ez J-M. Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer. Anti Cancer Agents Med Chem. 2013;13(3):483\u201395.","journal-title":"Anti Cancer Agents Med Chem"},{"issue":"2","key":"416_CR13","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1210\/jcem.86.2.7226","volume":"86","author":"M Klein","year":"2001","unstructured":"Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):656\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"416_CR14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejso.2010.10.010","volume":"37","author":"A Salajegheh","year":"2011","unstructured":"Salajegheh A, Smith RA, Kasem K, et al. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur J Surg Oncol. 2011;37(1):93\u20139.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"416_CR15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/SLA.0b013e31815fa447","volume":"247","author":"XM Yu","year":"2008","unstructured":"Yu XM, Lo CY, Lam AK, et al. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg. 2008;247(3):483\u20139.","journal-title":"Ann Surg"},{"key":"416_CR16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1530\/EJE-11-0631","volume":"166","author":"M Schlumberger","year":"2012","unstructured":"Schlumberger M, Sherman SI. Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol. 2012;166:5\u201311.","journal-title":"Eur J Endocrinol"},{"key":"416_CR17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2174\/1389202915999140404101902","volume":"15","author":"P Fallahi","year":"2014","unstructured":"Fallahi P, Ferrari SM, Mazzi V, et al. Personalization of targeted therapy in advanced thyroid cancer. Curr Genomics. 2014;15:190\u2013202.","journal-title":"Curr Genomics"},{"issue":"7","key":"416_CR18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621\u201330.","journal-title":"N Engl J Med"},{"key":"416_CR19","unstructured":"Bayer Pharma AG. Nexavar 200 mg film-coated tablets. EU summary of product characteristics. 2015. http:\/\/www.ema.europa.eu . Accessed 3 Sep 2015."},{"key":"416_CR20","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Nexavar (sorafenib) tablets, oral. US prescribing information. 2015. http:\/\/www.accessdata.fda . gov. Accessed 3 Sep 2015."},{"key":"416_CR21","unstructured":"Eisai Europe Ltd. Lenvima 4mg hard capsules: summary of product characteristics. 2015. http:\/\/www.ema.europa.eu . Accessed 17 Aug 2015."},{"key":"416_CR22","unstructured":"Eisai Inc. Lenvima (lenvatinib) capsules, for oral use: US prescribing information. 2015. http:\/\/www.lenvima.com . Accessed 17 Aug 2015."},{"key":"416_CR23","unstructured":"Eisai Co. Ltd. Eisai receives approval in Japan for anticancer agent Lenvima\u00ae (lenvatinib mesylate) as treatment for unresectable thyroid cancer [news release]. 2015. http:\/\/www.eisai.com . Accessed 3 Sep 2015."},{"issue":"5","key":"416_CR24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40265-015-0383-0","volume":"75","author":"LJ Scott","year":"2015","unstructured":"Scott LJ. Lenvatinib: first global approval. Drugs. 2015;75(5):553\u201360.","journal-title":"Drugs"},{"key":"416_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/638747","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (E7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014. doi: 10.1155\/2014\/638747 .","journal-title":"J Thyroid Res"},{"issue":"12","key":"416_CR26","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis. A crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011;2(12):1097\u2013105.","journal-title":"Genes Cancer"},{"issue":"1","key":"416_CR27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1021\/ml500394m","volume":"6","author":"K Okamoto","year":"2015","unstructured":"Okamoto K, Ikemori-Kawada M, Jestel A, et al. Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett. 2015;6(1):89\u201394.","journal-title":"ACS Med Chem Lett"},{"issue":"6","key":"416_CR28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00280-014-2444-6","volume":"73","author":"RC Shumaker","year":"2014","unstructured":"Shumaker RC, Zhou M, Ren M, et al. Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers. Cancer Chemother Pharmacol. 2014;73(6):1109\u201317.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"416_CR29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cpdd.140","volume":"4","author":"R Shumaker","year":"2015","unstructured":"Shumaker R, Aluri J, Fan J, et al. Effects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers. Clin Pharmacol Drug Dev. 2015;4(2):155\u201360.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"416_CR30","first-page":"651","volume":"34","author":"RC Shumaker","year":"2014","unstructured":"Shumaker RC, Aluri J, Fan J, et al. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. ClinDrug Investig. 2014;34(9):651\u20139.","journal-title":"ClinDrug Investig"},{"issue":"16","key":"416_CR31","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/cncr.29395","volume":"121","author":"ME Cabanillas","year":"2015","unstructured":"Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015;121(16):2749\u201356.","journal-title":"Cancer"},{"key":"416_CR32","unstructured":"Eisai Inc. Evaluating the safety and efficacy of oral E7080 in medullary and iodine-131 refractory, unresectable differentiated thyroid cancers, stratified by histology. 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00784303 . Accessed 1 Nov 2015."},{"key":"416_CR33","unstructured":"Eisai Inc. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of lenvatinib (E7080) in 131I-refractory differentiated thyroid cancer. 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01321554 . Accessed 23 Oct 2015."},{"key":"416_CR34","doi-asserted-by":"crossref","unstructured":"Robinson B, Schlumberger M, Wirth L, et al. Characterization of tumor size changes over time from the Phase 3 Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid (SELECT) [abstract no. 1031P]. In: European Society for Medical Oncology Congress. 2014.","DOI":"10.1093\/annonc\/mdu340.46"},{"key":"416_CR35","doi-asserted-by":"crossref","unstructured":"Brose MS, Schlumberger M, Tahara M, et al. Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT [abstract no. 6048]. J Clin Oncol. 2015;33(Suppl).","DOI":"10.1200\/jco.2015.33.15_suppl.6048"},{"key":"416_CR36","doi-asserted-by":"crossref","unstructured":"Guo M, Sherman S, Wirth L, et al. Overall survival gain with lenvatinib vs. placebo in radioactive iodine refractory differentiated thyroid cancer (RR-DTC): an updated analysis [abstract]. In: European Cancer Congress. 2015.","DOI":"10.1016\/S0959-8049(16)31549-0"},{"key":"416_CR37","unstructured":"Robinson B, Schlumberger M,Wirth L, et al. Open-label extension phase outcomes of the phase 3 Select trial of lenvatinib in patients with 131I-refractory differentiated thyroid cancer [abstract no. OR44]. In: 97th Annual Meeting of the Endocrine Society. 2015."},{"issue":"1","key":"416_CR38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CAD.0b013e3283161012","volume":"20","author":"V Launay-Vacher","year":"2009","unstructured":"Launay-Vacher V, Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anti-Cancer Drugs. 2009;20(1):81\u20132.","journal-title":"Anti-Cancer Drugs"},{"key":"416_CR39","unstructured":"Eisai Inc. An expanded access program with lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer. 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02211222 . Accessed 23 Oct 2015."},{"key":"416_CR40","unstructured":"Center for Drug Evaluation and Research. Application number: 206947Orig1s000. Medical review(s). 2015. http:\/\/www.accessdata.fda.gov . Accessed 1 Sep 2015."},{"issue":"9940","key":"416_CR41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet. 2014;384(9940):319\u201328.","journal-title":"Lancet"},{"key":"416_CR42","unstructured":"Tremblay G, Li X, Abouzaid S, et al. Number-needed-to-treat (NNT) analysis of therapies in radioiodine-refractory differentiated thyroid cancer (RR-DTC) using indirect comparison [abstract]. In: 15th International Thyroid Congress and 85th Annual Meeting of the American Thyroid Association. 2015."},{"issue":"2","key":"416_CR43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1634\/theoncologist.2014-0313","volume":"20","author":"JJ Gruber","year":"2015","unstructured":"Gruber JJ, Dimitrios CA. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist. 2015;20(2):113\u201326.","journal-title":"Oncologist"},{"key":"416_CR44","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(12)70335-2","volume":"13","author":"S Leboulleux","year":"2012","unstructured":"Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13:897\u2013905.","journal-title":"Lancet Oncol"},{"key":"416_CR45","unstructured":"Zhao Y. Lenvatinib in the management of differentiated thyroid cancer. 2015. http:\/\/targetedonc.com . Accessed 27 Oct 2015."},{"key":"416_CR46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1127","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Jarzab B, Cabanillas ME, et al. A phase 2 trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). Clin Cancer Res. 2015. doi: 10.1158\/1078-0432.CCR-15-1127 .","journal-title":"Clin Cancer Res"},{"key":"416_CR47","doi-asserted-by":"crossref","unstructured":"Takahashi S, Tahara M, Kiyota N, et al. Phase II study of lenvatinib, a multitargeted tyrosine kinase inhibitor, in patients with all histologic subtypes of advanced thyroid cancer (differentiated, medullary, and anaplastic) [abstract no. 995PD]. In: European Society for Medical Oncology Congress. 2014.","DOI":"10.1093\/annonc\/mdu340.10"},{"key":"416_CR48","doi-asserted-by":"publisher","unstructured":"Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18. doi: 10.1186\/2045-824X-6-18 .","DOI":"10.1186\/2045-824X-6-18"},{"issue":"3","key":"416_CR49","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122(3):664\u201371.","journal-title":"Int J Cancer"},{"issue":"1","key":"416_CR50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","volume":"340","author":"K Okamoto","year":"2013","unstructured":"Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1):97\u2013103.","journal-title":"Cancer Lett"},{"issue":"17","key":"416_CR51","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","volume":"14","author":"J Matsui","year":"2008","unstructured":"Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lungmetastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14(17):5459\u201365.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"416_CR52","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5414\/CP201937","volume":"52","author":"R Shumaker","year":"2014","unstructured":"Shumaker R, Aluri J, Fan J, et al. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers. Int J Clin Pharmacol. 2014;52(4):284\u201391.","journal-title":"Int J Clin Pharmacol"},{"issue":"1","key":"416_CR53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10637-014-0181-7","volume":"33","author":"AC Dubbelman","year":"2015","unstructured":"Dubbelman AC, Rosing H, Nijenhuis C, et al. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Investig New Drugs. 2015;33(1):233\u201340.","journal-title":"Investig New Drugs"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-015-0416-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-015-0416-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-015-0416-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-015-0416-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T09:35:39Z","timestamp":1567589739000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-015-0416-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["416"],"URL":"https:\/\/doi.org\/10.1007\/s11523-015-0416-3","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}